- Home
- AUPH vs ADNT Comparison
AUPH vs ADNT Comparison
Compare AUPH & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- ADNT
- Stock Information
- Founded
- AUPH 1993
- ADNT 2016
- Country
- AUPH Canada
- ADNT Ireland
- Employees
- AUPH N/A
- ADNT N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- ADNT Auto Parts:O.E.M.
- Sector
- AUPH Health Care
- ADNT Consumer Discretionary
- Exchange
- AUPH Nasdaq
- ADNT Nasdaq
- Market Cap
- AUPH 999.8M
- ADNT 1.1B
- IPO Year
- AUPH 1999
- ADNT N/A
- Fundamental
- Price
- AUPH $7.85
- ADNT $15.87
- Analyst Decision
- AUPH Strong Buy
- ADNT Hold
- Analyst Count
- AUPH 2
- ADNT 10
- Target Price
- AUPH $11.50
- ADNT $18.00
- AVG Volume (30 Days)
- AUPH 1.1M
- ADNT 1.3M
- Earning Date
- AUPH 05-12-2025
- ADNT 05-07-2025
- Dividend Yield
- AUPH N/A
- ADNT N/A
- EPS Growth
- AUPH N/A
- ADNT N/A
- EPS
- AUPH 0.27
- ADNT N/A
- Revenue
- AUPH $247,295,000.00
- ADNT $14,384,000,000.00
- Revenue This Year
- AUPH $11.86
- ADNT N/A
- Revenue Next Year
- AUPH $24.96
- ADNT $0.83
- P/E Ratio
- AUPH $29.71
- ADNT N/A
- Revenue Growth
- AUPH 29.20
- ADNT N/A
- 52 Week Low
- AUPH $4.98
- ADNT $10.04
- 52 Week High
- AUPH $10.67
- ADNT $31.19
- Technical
- Relative Strength Index (RSI)
- AUPH 44.68
- ADNT 73.51
- Support Level
- AUPH $7.89
- ADNT $15.50
- Resistance Level
- AUPH $8.49
- ADNT $16.24
- Average True Range (ATR)
- AUPH 0.30
- ADNT 0.59
- MACD
- AUPH -0.02
- ADNT 0.46
- Stochastic Oscillator
- AUPH 36.95
- ADNT 91.49
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.